BR112014004902A2 - peptídeos - Google Patents
peptídeosInfo
- Publication number
- BR112014004902A2 BR112014004902A2 BR112014004902A BR112014004902A BR112014004902A2 BR 112014004902 A2 BR112014004902 A2 BR 112014004902A2 BR 112014004902 A BR112014004902 A BR 112014004902A BR 112014004902 A BR112014004902 A BR 112014004902A BR 112014004902 A2 BR112014004902 A2 BR 112014004902A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161528804P | 2011-08-30 | 2011-08-30 | |
| GB1115014.1 | 2011-08-30 | ||
| US61/528,804 | 2011-08-30 | ||
| GBGB1115014.1A GB201115014D0 (en) | 2011-08-30 | 2011-08-30 | Peptides |
| GB1211740.4 | 2012-07-03 | ||
| GBGB1211740.4A GB201211740D0 (en) | 2012-07-03 | 2012-07-03 | Peptides |
| PCT/GB2012/052116 WO2013030569A2 (en) | 2011-08-30 | 2012-08-29 | Peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014004902A2 true BR112014004902A2 (pt) | 2017-07-04 |
| BR112014004902B1 BR112014004902B1 (pt) | 2022-02-08 |
Family
ID=47756980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014004902-5A BR112014004902B1 (pt) | 2011-08-30 | 2012-08-29 | Peptídeo, composição farmacêutica ou medicamento compreendendo o dito peptídeo e uso do mesmo para tratar distrofia muscular de duchenne |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9302014B2 (pt) |
| EP (1) | EP2751128B1 (pt) |
| JP (1) | JP6077543B2 (pt) |
| CN (1) | CN103998458B (pt) |
| AU (1) | AU2012300633B2 (pt) |
| BR (1) | BR112014004902B1 (pt) |
| CA (1) | CA2846218C (pt) |
| ES (1) | ES2876939T3 (pt) |
| IN (1) | IN2014MN00357A (pt) |
| WO (1) | WO2013030569A2 (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10188708B2 (en) | 2014-01-13 | 2019-01-29 | Berg Llc | Enolase 1 (Eno1) compositions and uses thereof |
| US20170197011A1 (en) * | 2014-06-06 | 2017-07-13 | Vivoscript, Inc. | Methods for repairing cartilage damage |
| CN106390100B (zh) * | 2015-01-28 | 2021-06-22 | 中国科学院天津工业生物技术研究所 | 一种多肽复合物作为glp-1药物载体的应用、方法及其融合蛋白复合物 |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| CA3010599C (en) * | 2016-01-06 | 2025-05-20 | Stealth Biotherapeutics Inc. | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY |
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| CN109477109B (zh) | 2016-04-29 | 2022-09-23 | 萨勒普塔医疗公司 | 靶向人lmna的寡核苷酸类似物 |
| EP4067368A1 (en) | 2016-06-01 | 2022-10-05 | Athira Pharma, Inc. | Compounds |
| CA3029772A1 (en) | 2016-07-05 | 2018-01-11 | Biomarin Technologies B.V. | Pre-mrna splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders |
| MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| US20200131231A1 (en) * | 2017-02-17 | 2020-04-30 | Oxford University Innovation Limited | Cell penetrating peptides |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| TW201919682A (zh) | 2017-08-08 | 2019-06-01 | 西班牙商阿爾米雷爾有限公司 | 活化Nrf2路徑的新穎化合物 |
| WO2019070962A1 (en) * | 2017-10-04 | 2019-04-11 | Ohio State Innovation Foundation | BICYCLIC PEPTIDE INHIBITORS |
| CN108070025B (zh) * | 2017-10-24 | 2019-11-19 | 中山大学附属口腔医院 | 一种细胞穿透肽和细胞穿透肽复合物及二者的应用 |
| EP3746105A4 (en) | 2018-01-29 | 2022-05-18 | Ohio State Innovation Foundation | CYCLIC PEPTIDYLIN HIBITORS OF THE CAL-PDZ-BINDING DOMAIN |
| EP3784248A4 (en) * | 2018-04-26 | 2022-08-10 | Sarepta Therapeutics, Inc. | EXON-SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY |
| US11559586B2 (en) * | 2018-05-22 | 2023-01-24 | Children's Medical Center Corporation | Nanoparticles for treatment of choroidal neovascularization and other indications |
| GB201812972D0 (en) * | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812980D0 (en) * | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| CN113453723A (zh) | 2018-12-07 | 2021-09-28 | 牛津大学科技创新有限公司 | 接头 |
| CN113660938A (zh) * | 2019-01-30 | 2021-11-16 | 国立研究开发法人国立精神·神经医疗研究中心 | 核酸递送复合物 |
| GB201911403D0 (en) * | 2019-08-09 | 2019-09-25 | Univ Oxford Innovation Ltd | Conjugate and uses thereof |
| WO2022192749A2 (en) * | 2021-03-12 | 2022-09-15 | Pepgen Inc. | Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates |
| AU2022312170A1 (en) | 2021-07-16 | 2024-02-08 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Oligonucleotide for inhibiting quaking activity |
| US20240390508A1 (en) | 2021-08-21 | 2024-11-28 | Takeda Pharmaceutical Company Limited | Human transferrin receptor binding peptide-drug conjugate |
| PE20251277A1 (es) | 2022-05-06 | 2025-05-14 | Academisch Ziekenhuis Leiden | Oligonucleotido |
| GB202216207D0 (en) * | 2022-11-01 | 2022-12-14 | Univ Oxford Innovation Ltd | Shortened cell-penetrating peptides |
| GB202411696D0 (en) | 2024-08-08 | 2024-09-25 | Univ Oxford Innovation Ltd | Therapeutic nucleic acids for treating genetic disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL142869A0 (en) | 1998-11-13 | 2002-03-10 | Cyclacel Ltd | Transport vectors |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| EP3443976A1 (en) | 2007-06-29 | 2019-02-20 | Sarepta Therapeutics, Inc. | Tissue specific peptide conjugates and methods |
| US20110130346A1 (en) | 2008-05-30 | 2011-06-02 | Isis Innovation Limited | Peptide conjugates for delvery of biologically active compounds |
| US8575305B2 (en) * | 2008-06-04 | 2013-11-05 | Medical Research Council | Cell penetrating peptides |
| WO2011064552A1 (en) * | 2009-11-30 | 2011-06-03 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
-
2012
- 2012-08-29 CN CN201280042628.7A patent/CN103998458B/zh active Active
- 2012-08-29 BR BR112014004902-5A patent/BR112014004902B1/pt active IP Right Grant
- 2012-08-29 ES ES12756546T patent/ES2876939T3/es active Active
- 2012-08-29 AU AU2012300633A patent/AU2012300633B2/en active Active
- 2012-08-29 US US14/240,832 patent/US9302014B2/en active Active
- 2012-08-29 WO PCT/GB2012/052116 patent/WO2013030569A2/en not_active Ceased
- 2012-08-29 EP EP12756546.3A patent/EP2751128B1/en active Active
- 2012-08-29 IN IN357MUN2014 patent/IN2014MN00357A/en unknown
- 2012-08-29 CA CA2846218A patent/CA2846218C/en active Active
- 2012-08-29 JP JP2014527734A patent/JP6077543B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IN2014MN00357A (pt) | 2015-06-19 |
| EP2751128A2 (en) | 2014-07-09 |
| JP2014526238A (ja) | 2014-10-06 |
| CA2846218C (en) | 2020-09-01 |
| AU2012300633B2 (en) | 2017-04-27 |
| CN103998458B (zh) | 2018-10-09 |
| EP2751128B1 (en) | 2021-03-03 |
| ES2876939T3 (es) | 2021-11-15 |
| BR112014004902B1 (pt) | 2022-02-08 |
| AU2012300633A8 (en) | 2014-05-29 |
| WO2013030569A3 (en) | 2013-06-13 |
| US20140342992A1 (en) | 2014-11-20 |
| JP6077543B2 (ja) | 2017-02-08 |
| CN103998458A (zh) | 2014-08-20 |
| CA2846218A1 (en) | 2013-03-07 |
| WO2013030569A2 (en) | 2013-03-07 |
| AU2012300633A1 (en) | 2014-03-06 |
| US9302014B2 (en) | 2016-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014004902A2 (pt) | peptídeos | |
| DK2744810T4 (da) | Tenofovir-alafenamid-hemifumarat | |
| EP2715659A4 (en) | ABOUT FEED | |
| CO7020866A2 (es) | Péptidos terapéuticos | |
| CO6900146A2 (es) | Imidazopiridazinas sustituidas con amino | |
| DK2769050T3 (da) | Propsensor | |
| DK2797616T3 (da) | Celle-penetrerende peptider | |
| EP2752374A4 (en) | gooseneck | |
| EP2795884A4 (en) | Audio conferencing | |
| BR112014000879A2 (pt) | deflegmador | |
| DK3272861T3 (da) | Alpha-galactosidase-sammensætninger | |
| CO6960543A2 (es) | 2-tiopirimidinonas | |
| EP2786752A4 (en) | Ropinirole-containing adhesive patch | |
| FI20116212L (fi) | Polypeptidi | |
| EP2723481A4 (en) | FLOW COMPENSATOR | |
| DK3141251T3 (da) | Koloskopi - forberedelse | |
| EP2708561A4 (en) | BIO-PIN | |
| CL2014002180A1 (es) | Peptidos antomicrobianos | |
| EP2715068A4 (en) | Tunneling apparatus | |
| BR112013024323A2 (pt) | peptídeos neuroprotetores | |
| EP2762923A4 (en) | RADIATION MEASURING DEVICE | |
| EP2760803A4 (en) | Geopolymer product | |
| DE112012000958A5 (de) | Handsäge | |
| EP2771685A4 (en) | BIOMARKERS OF CANCER | |
| EP2729467A4 (en) | CRYPTATE COMPOUNDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: UNITED KINGDOM RESEARCH AND INNOVATION (GB) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/08/2012, OBSERVADAS AS CONDICOES LEGAIS. |